ERBB2 and breast carcinoma: However, a combination of these doses resulted in 80% growth inhibition of SKBR3 breast cancer cells (Fig. 1A), suggesting a significant inhibitory effect of combination treatment in HER-2/neu-expressing breast cancer cells.